Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6616 to 6630 of 8314 results

  1. Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)

    This guideline has been updated and replaced by NICE guideline NG185.

    Technology appraisal guidance
    Published
    27 July 2011

  2. Retigabine for the adjunctive treatment of partial onset seizures in epilepsy (TA232)

    The guidance has been withdrawn because GlaxoSmithKline has discontinued retigabine (Trobalt) due to limited usage.

    Technology appraisal guidance
    Published
    27 July 2011

  3. Golimumab for the treatment of ankylosing spondylitis (TA233)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Technology appraisal guidance
    Published
    24 August 2011

  4. Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (TA234)

    This guidance has been updated and replaced by NICE technology appraisal guidance 280.

    Technology appraisal guidance
    Published
    24 August 2011

  5. Ranibizumab for the treatment of diabetic macular oedema (TA237)

    This guidance has been updated and replaced by NICE technology appraisal guidance 274.

    Technology appraisal guidance
    Published
    30 November 2011

  6. Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)

    This guidance has been updated and replaced by NICE technology appraisal guidance 432.

    Technology appraisal guidance
    Published
    19 April 2011

  7. Orlistat for the treatment of obesity in adults (TA22)

    This guidance has been replaced by NICE guideline CG43.

    Technology appraisal guidance
    Published
    27 March 2001

  8. Trabectedin for the treatment of relapsed ovarian cancer (TA222)

    This guidance has been updated and replaced by NICE technology appraisal guidance 389.

    Technology appraisal guidance
    Published
    27 April 2011

  9. Wound care - debriding agents (TA24)

    This guidance has been replaced by NICE guideline CG74.

    Technology appraisal guidance
    Published
    27 April 2001

  10. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (TA241)

    This guidance has been updated and replaced by NICE technology appraisal guidance 425.

    Technology appraisal guidance
    Published
    13 January 2012

  11. Roflumilast for the management of severe chronic obstructive pulmonary disease (TA244)

    This guidance has been updated and replaced by NICE technology appraisal guidance 461.

    Technology appraisal guidance
    Published
    25 January 2012

  12. Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal) (TA262)

    This guidance has been updated and replaced by NICE technology appraisal guidance 329.

    Technology appraisal guidance
    Published
    25 July 2012

  13. The clinical effectiveness and cost effectiveness of surgery for people with morbid obesity (TA46)

    This guidance has been updated and replaced by NICE guideline CG43.

    Technology appraisal guidance
    Published
    19 July 2002

  14. Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465)

    This guidance has been withdrawn because olaratumumab (Lartruvo) no longer has a marketing authorisation.

    Technology appraisal guidance
    Published
    9 August 2017

  15. Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) (TA470)

    This advice has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Technology appraisal guidance
    Published
    23 August 2017